

## Solomon Islands

### Support for Vaccine: Measles Rubella

#### This Decision Letter sets out the Programme Terms of a Programme

<b>1. Country:</b>	Solomon Islands						
<b>2. Vaccine grant number:</b>	19-SLB-34a-X, 19-SLB-35a-Y						
<b>3. Date of Decision Letter:</b>	20-05-19						
<b>4. Date of the Partnership Framework Agreement:</b>	29-04-13						
<b>5. Programme title:</b>	New Vaccine Support (NVS), Measles Rubella, Follow-up campaign						
<b>6. Vaccine type:</b>	Measles Rubella						
<b>7. Requested product presentation and formulation of vaccine:</b>	Measles Rubella, 10 dose(s) per vial, LYOPHILISED						
<b>8. Programme Duration:<sup>1</sup></b>	2019						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	n/a	2019	2020	2021	2022	2023	Total <sup>2</sup>
Programme Budget (US\$)	n/a	63,000	-	-	-	-	63,000
<b>10. Vaccine introduction grant</b>	Not applicable						
<b>11. Product switch grant</b>	Not applicable						
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
<b>Type of supplies to be purchased</b>	n/a	2019	2020				
Number of vaccine doses		96,300	-				
Annual Amounts (US\$)	n/a	63,000	-				
<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
<b>14. Self-procurement:</b>	Not applicable						
<b>15. Co-financing obligations:</b>	According to the co-financing policy, the Country falls within the group: Accelerated transition phase						
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.							

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021	2022	2023
Number of vaccine doses	5,100	-	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	3,241	-	-	-	-
Total co-financing payments (US\$) (including freight)	3,500	-	-	-	-

**16. Operational support for catch-up campaigns:**

Year	Grant Number	Amount
2019	19-SLB-35a-Y	69,106

**17. Additional Reporting Requirements:**


	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock, by end of March;</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

**18. Financial clarifications:**  
Not applicable

**19. Other conditions:**  
Not applicable

Signed by,

On behalf of Gavi



Hind Khatib-Othman

Managing Director, Country Programmes

20/05/2019